Delving into the Latest Updates on Unitary Enterprise UNITEHPROM BSU with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

A Prospective, Randomized, Parallel, Single-blind Clinical Study of the Effectiveness, Tolerability and Safety of the Drug "Anti-spike, Gel, 100 g in Bottles in Package No. 1" Produced by the Republican Unitary Enterprise "Unitekhprom BSU", Belarus, With a Single Intraperitoneal Use After Surgical Interventions in Adult Patients With Acute Phlegmonous Appendicitis

The purpose of the clinical trials is the evaluation of the effectiveness and safety of a single intraperitoneal use of the drug "Antispike, gel, 100 g in a bottle" produced by Unitary Enterprise Unitehprom BSU, Belarus in patients after surgical control of acute phlegmonous appendicitis to prevent abdominal adhesions.

Start Date19 Mar 2025

Sponsor / Collaborator

Unitary Enterprise UNITEHPROM BSU

NCT06232434

/ RecruitingPhase 2/3IIT

An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II

It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patients with disseminated gastric cancer.
In total, the study plans to include 120 patients aged 18 to 75 years inclusive, including 60 patients in the study group and 60 in the comparison group. The study consists of daily examination of patients throughout the entire period of hospitalization and subsequent visits.

Start Date19 Mar 2025

Sponsor / Collaborator

Unitary Enterprise UNITEHPROM BSU

100 Clinical Results associated with Unitary Enterprise UNITEHPROM BSU

Login to view more data

0 Patents (Medical) associated with Unitary Enterprise UNITEHPROM BSU

Login to view more data

1

Literatures (Medical) associated with Unitary Enterprise UNITEHPROM BSU

Proceedings of the National Academy of Sciences of Belarus, Chemical Series

Dextran phosphate stabilized selenium nanoparticles for creating a prolonged-release form of doxorubicin

Author: Yunusov, Kh. ; Sarymsakov, A. ; Alinovskaya, V. А. ; Karcheuskaya, A. G. ; Aharodnikau, U E. ; Rashidova, S. ; Bychkovsky, P. M. ; Baranouskaya, A. V. ; Yedchyk, A. V. ; Pristromova, Yu. I. ; Yurkshtovich, T. L.

Nanobiotechnology is an actively developing field of science, which finds application in cancer therapy, molecular diagnostics and molecular imaging. In this work, selenium nanoparticles were successfully obtained by chemical reduction of selenite ions with ascorbic acid in dextran phosphate (DP) solutions, which was used as a stabilizer. It has been found that dextran phosphate coated nanoparticles are stable during storage for 3 days. Sorption of the antitumor substance doxorubicin was studied in the concentration range from 0.1 mg/ml to 1 mg/ml. A significant prolongation of cytostatic release from stabilized nanoparticles was shown. Selenium nanoparticles coated with water-soluble DP can be used to create broad-spectrum drugs, in particular, antitumor drugs that compensate for selenium deficiency in the body.

100 Deals associated with Unitary Enterprise UNITEHPROM BSU

Login to view more data

100 Translational Medicine associated with Unitary Enterprise UNITEHPROM BSU

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data